About 14 results found for searched term "JAK-IN-11" (0.122 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41708 | JAK1-IN-11 | JAK |
| JAK1-IN-11 is a potent inhibitor of JAK, with IC50s of 0.02 nM (JAK1), and 0.44 nM (JAK2), respectively. | ||
| M49555 | JAK-IN-11 | JAK |
| JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. | ||
| M49592 | JAK3-IN-11 | JAK |
| JAK3-IN-11 , a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. | ||
| M1700 | Momelotinib (CYT387) | JAK |
| LM-1149; Momelotinib; CYT 11387 | ||
| Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. | ||
| M4912 | GLPG0634 analogue | JAK |
| GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. | ||
| M7551 | Solcitinib | JAK |
| GSK-2586184; GLPG-0778 | ||
| Solcitinib is an oral, competitive, potent, and selective JAK1 inhibitor with an IC50 value of 9.8 nM, which is 11,55, and 23 times more selective than JAK2, JAK3, and TYK2. Solcitinib can be used in studies of psoriasis. | ||
| M10417 | Delphinidin chloride | JAK |
| delfinidolchloride | ||
| Delphinidin (chloride) is an anthocyanidin, a natural plant pigment which can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells. | ||
| M41700 | Gusacitinib hydrochloride | JAK |
| Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. | ||
| M49565 | Ilunocitinib | JAK |
| Ilunocitinib is a JAK inhibitor (extracted from patent WO2009114512A1). | ||
| M49577 | JAK1-IN-8 | JAK |
| JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. | ||
| M49585 | JAK2-IN-7 | JAK |
| JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. | ||
| M49586 | JAK3 covalent inhibitor-1 | JAK |
| JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. | ||
| M49594 | JAK3-IN-7 | JAK |
| JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. | ||
| M49776 | SJ10542 | PROTAC |
| SJ10542 is a potent and selective JAK2/3 directing phenyl glutarimide (PG)-PROTAC with DC50s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
